Pharma BD Deal Intelligence

Azurity Pharmaceuticals / PolyPid Ltd.

2026 · Licensing/Option · $330M · Complete

PolyPid granted Azurity Pharmaceuticals exclusive rights to commercialize D-PLEX100 for the prevention of surgical site infections in the United States and Canada, following positive Phase 3 SHIELD II results. PolyPid receives $15 million upfront and a further $15 million on FDA acceptance of the NDA, with up to approximately $300 million in additional development, regulatory and sales milestones plus tiered mid-teen to mid-twenties percentage royalties; PolyPid retains manufacturing and ex-U.S./Canada rights.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals